TY - JOUR
T1 - Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA
T2 - Part II—An Updated Analysis of SEER-Medicare Data
AU - Shih, Ya Chen Tina
AU - Xu, Ying
AU - Chien, Chun-Ru
AU - Kim, Bumyang
AU - Shen, Yu
AU - Li, Liang
AU - Geynisman, Daniel M.
N1 - Funding Information:
The authors thank Dr. Gary Deyter, technical writer from the Department of Health Services Research at The University of Texas MD Anderson Cancer Center for his editorial contribution. The interpretation and reporting of these data are the responsibilities of the authors and should not be viewed as an official policy or interpretation of the National Cancer Institute. This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute, the Office of Research, Development and Information, Centers for Medicare & Medicaid Services, Information Management Services, Inc., and the SEER Program tumor registries in the creation of the SEER-Medicare database.
Funding Information:
We acknowledge funding from the China Medical University Hospital (Chien, CRS-108-054) and the National Cancer Institute (Shih, R01 CA207216, R01 CA225646, R01 CA225647 and CCSG P30 CA016672; Li R01 CA225646; Shen Cancer Center Biostatistics Shared Resource CA016672).
Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: The influx of new oncologic technologies has changed the treatment landscape of renal cell carcincoma (RCC) in the last decade. This study updated a previously published paper on the economic burden of RCC in the USA by using more recent data to examine the impact of various forms of new oncologic technologies on the economic burden of RCC. Methods: Using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we employed prevalence and incidence costing approaches to estimate RCC costs from the payer’s perspective. We conducted a longitudinal analysis of cost data per patient per month for a prevalence cohort of patients with RCC to determine which category of new technology (surgery, radiation, or cancer drugs) was the major cost driver for RCC. We then applied the incidence costing approach to estimate costs related to RCC by care phase (initial, continuing, and terminal) and compared costs between two incidence cohorts to examine how new technology affected the economic burden of RCC over time. Results: After controlling for demographic factors, clinical characteristics, neighborhood socioeconomic status, and time trend, we found that rising per patient per month costs were driven by new technologies in cancer drugs. Incidence-based analysis showed the annual net cost (2018 US$) for patients with distant-stage RCC diagnosed between 2002 and 2006 was $51,639, $19,025, $76,603, and $29,045 for the initial, continuing (year 1), terminal (died from RCC), and terminal (died from other causes) care phases, respectively. Costs increased to $70,703, $34,716, $107,989, and $47,538, respectively, for the incidence cohort diagnosed between 2007 and 2011. Conclusion: The rising economic burden of RCC was most pronounced among patients with distant-stage RCC, and driven primarily by new cancer drugs.
AB - Background: The influx of new oncologic technologies has changed the treatment landscape of renal cell carcincoma (RCC) in the last decade. This study updated a previously published paper on the economic burden of RCC in the USA by using more recent data to examine the impact of various forms of new oncologic technologies on the economic burden of RCC. Methods: Using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we employed prevalence and incidence costing approaches to estimate RCC costs from the payer’s perspective. We conducted a longitudinal analysis of cost data per patient per month for a prevalence cohort of patients with RCC to determine which category of new technology (surgery, radiation, or cancer drugs) was the major cost driver for RCC. We then applied the incidence costing approach to estimate costs related to RCC by care phase (initial, continuing, and terminal) and compared costs between two incidence cohorts to examine how new technology affected the economic burden of RCC over time. Results: After controlling for demographic factors, clinical characteristics, neighborhood socioeconomic status, and time trend, we found that rising per patient per month costs were driven by new technologies in cancer drugs. Incidence-based analysis showed the annual net cost (2018 US$) for patients with distant-stage RCC diagnosed between 2002 and 2006 was $51,639, $19,025, $76,603, and $29,045 for the initial, continuing (year 1), terminal (died from RCC), and terminal (died from other causes) care phases, respectively. Costs increased to $70,703, $34,716, $107,989, and $47,538, respectively, for the incidence cohort diagnosed between 2007 and 2011. Conclusion: The rising economic burden of RCC was most pronounced among patients with distant-stage RCC, and driven primarily by new cancer drugs.
UR - http://www.scopus.com/inward/record.url?scp=85068850203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068850203&partnerID=8YFLogxK
U2 - 10.1007/s40273-019-00824-2
DO - 10.1007/s40273-019-00824-2
M3 - Article
C2 - 31286464
AN - SCOPUS:85068850203
SN - 1170-7690
VL - 37
SP - 1495
EP - 1507
JO - PharmacoEconomics
JF - PharmacoEconomics
IS - 12
ER -